View Financial HealthVimta Labs 배당 및 자사주 매입배당 기준 점검 4/6Vimta Labs 수익으로 충분히 충당되는 현재 수익률 0.44% 보유한 배당금 지급 회사입니다. 다음 지급일은 8th July, 2026 이며 배당락일은 다음과 같습니다. 18th June, 2026.핵심 정보0.4%배당 수익률-0.002%자사주 매입 수익률총 주주 수익률0.4%미래 배당 수익률n/a배당 성장률7.6%다음 배당 지급일08 Jul 26배당락일18 Jun 26주당 배당금n/a배당 성향11%최근 배당 및 자사주 매입 업데이트공시 • May 07Vimta Labs Limited announces Annual dividend, payable on July 08, 2026Vimta Labs Limited announced Annual dividend of INR 2.0000 per share payable on July 08, 2026, ex-date on June 18, 2026 and record date on June 18, 2026.공시 • Jun 07Vimta Labs Limited Approves Dividend for the Financial Year Ended March 31, 2025Vimta Labs Limited announced at annual general meeting held on June 6, 2025, the shareholders approved to declare a dividend of INR 2 per equity share for the financial year ended March 31, 2025.Upcoming Dividend • May 23Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 30 May 2025. Payment date: 16 June 2025. Payout ratio is a comfortable 6.7% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.4%).공시 • Jul 18Vimta Labs Limited Approves Dividend for the Year Ended March 31, 2024Vimta Labs Limited announced that at its AGM held on July 18, 2024, shareholders approved the dividend of INR 2 per equity shares for the financial year ended March 31, 2024.Upcoming Dividend • Jul 04Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 11 July 2024. Payment date: 25 July 2024. Payout ratio is a comfortable 11% but the company is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.6%).공시 • Jun 29Vimta Labs Limited Declares Dividend for the Financial Year Ended March 31, 2023Vimta Labs Limited at its 33rd Annual General Meeting held on 28 June 2023, declared a dividend of INR 2 per equity share for the financial year ended March 31, 2023.모든 업데이트 보기Recent updates분석 기사 • May 16Do Vimta Labs' (NSE:VIMTALABS) Earnings Warrant Your Attention?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...New Risk • May 15New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.Reported Earnings • May 07Full year 2026 earnings released: EPS: ₹17.40 (vs ₹15.01 in FY 2025)Full year 2026 results: EPS: ₹17.40 (up from ₹15.01 in FY 2025). Revenue: ₹4.16b (up 21% from FY 2025). Net income: ₹775.1m (up 16% from FY 2025). Profit margin: 19% (in line with FY 2025). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.공시 • May 07Vimta Labs Limited announces Annual dividend, payable on July 08, 2026Vimta Labs Limited announced Annual dividend of INR 2.0000 per share payable on July 08, 2026, ex-date on June 18, 2026 and record date on June 18, 2026.공시 • May 06Vimta Labs Limited, Annual General Meeting, Jun 25, 2026Vimta Labs Limited, Annual General Meeting, Jun 25, 2026.New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.분석 기사 • Jan 30Vimta Labs Limited (NSE:VIMTALABS) May Have Run Too Fast Too Soon With Recent 29% Price PlummetTo the annoyance of some shareholders, Vimta Labs Limited ( NSE:VIMTALABS ) shares are down a considerable 29% in the...Reported Earnings • Jan 29Third quarter 2026 earnings released: EPS: ₹3.96 (vs ₹3.93 in 3Q 2025)Third quarter 2026 results: EPS: ₹3.96 (up from ₹3.93 in 3Q 2025). Revenue: ₹1.00b (up 12% from 3Q 2025). Net income: ₹175.9m (flat on 3Q 2025). Profit margin: 18% (down from 20% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.분석 기사 • Jan 14Estimating The Fair Value Of Vimta Labs Limited (NSE:VIMTALABS)Key Insights Vimta Labs' estimated fair value is ₹510 based on 2 Stage Free Cash Flow to Equity With ₹550 share price...Buy Or Sell Opportunity • Jan 07Now 21% overvaluedOver the last 90 days, the stock has fallen 14% to ₹618. The fair value is estimated to be ₹510, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has grown by 16%.Buy Or Sell Opportunity • Dec 22Now 20% overvaluedOver the last 90 days, the stock has fallen 18% to ₹619. The fair value is estimated to be ₹515, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has grown by 16%.Buy Or Sell Opportunity • Nov 25Now 20% overvaluedOver the last 90 days, the stock has fallen 2.6% to ₹615. The fair value is estimated to be ₹512, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has grown by 16%.Reported Earnings • Nov 04Second quarter 2026 earnings released: EPS: ₹4.46 (vs ₹3.84 in 2Q 2025)Second quarter 2026 results: EPS: ₹4.46 (up from ₹3.84 in 2Q 2025). Revenue: ₹1.05b (up 23% from 2Q 2025). Net income: ₹199.2m (up 17% from 2Q 2025). Profit margin: 19% (down from 20% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Sep 02Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹764, the stock trades at a trailing P/E ratio of 47.3x. Average trailing P/E is 41x in the Life Sciences industry in India. Total returns to shareholders of 333% over the past three years.분석 기사 • Aug 28Some Shareholders Feeling Restless Over Vimta Labs Limited's (NSE:VIMTALABS) P/E RatioVimta Labs Limited's ( NSE:VIMTALABS ) price-to-earnings (or "P/E") ratio of 39.2x might make it look like a sell right...Valuation Update With 7 Day Price Move • Jul 28Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹659, the stock trades at a trailing P/E ratio of 40.7x. Average trailing P/E is 53x in the Life Sciences industry in India. Total returns to shareholders of 229% over the past three years.Reported Earnings • Jul 18First quarter 2026 earnings released: EPS: ₹4.25 (vs ₹2.77 in 1Q 2025)First quarter 2026 results: EPS: ₹4.25 (up from ₹2.77 in 1Q 2025). Revenue: ₹993.1m (up 22% from 1Q 2025). Net income: ₹188.9m (up 54% from 1Q 2025). Profit margin: 19% (up from 15% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Jun 12New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.공시 • Jun 07Vimta Labs Limited Approves Dividend for the Financial Year Ended March 31, 2025Vimta Labs Limited announced at annual general meeting held on June 6, 2025, the shareholders approved to declare a dividend of INR 2 per equity share for the financial year ended March 31, 2025.분석 기사 • May 31Vimta Labs Limited's (NSE:VIMTALABS) CEO Looks Like They Deserve Their Pay PacketKey Insights Vimta Labs' Annual General Meeting to take place on 6th of June Total pay for CEO Harita Vasireddi...Upcoming Dividend • May 23Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 30 May 2025. Payment date: 16 June 2025. Payout ratio is a comfortable 6.7% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.4%).공시 • May 16Vimta Labs Limited, Annual General Meeting, Jun 06, 2025Vimta Labs Limited, Annual General Meeting, Jun 06, 2025, at 10:00 Indian Standard Time.Reported Earnings • May 16Full year 2025 earnings released: EPS: ₹30.28 (vs ₹18.51 in FY 2024)Full year 2025 results: EPS: ₹30.28 (up from ₹18.51 in FY 2024). Revenue: ₹3.48b (up 9.1% from FY 2024). Net income: ₹667.6m (up 63% from FY 2024). Profit margin: 19% (up from 13% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth.분석 기사 • May 16Here's Why Vimta Labs (NSE:VIMTALABS) Has Caught The Eye Of InvestorsInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...공시 • May 15+ 3 more updatesVimta Labs Limited to Report First Half, 2026 Results on Nov 14, 2025Vimta Labs Limited announced that they will report first half, 2026 results on Nov 14, 2025공시 • Apr 24Vimta Labs Limited to Report Q4, 2025 Results on Apr 28, 2025Vimta Labs Limited announced that they will report Q4, 2025 results on Apr 28, 2025Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹853, the stock trades at a trailing P/E ratio of 34.7x. Average trailing P/E is 43x in the Life Sciences industry in India. Total returns to shareholders of 128% over the past three years.Valuation Update With 7 Day Price Move • Mar 10Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹1,003, the stock trades at a trailing P/E ratio of 40.6x. Average trailing P/E is 48x in the Life Sciences industry in India. Total returns to shareholders of 198% over the past three years.Valuation Update With 7 Day Price Move • Feb 21Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹947, the stock trades at a trailing P/E ratio of 38.6x. Average trailing P/E is 50x in the Life Sciences industry in India. Total returns to shareholders of 197% over the past three years.Recent Insider Transactions • Feb 19Key Executive recently sold ₹3.1m worth of stockOn the 12th of February, V. Vungal sold around 3k shares on-market at roughly ₹1,084 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹5.8m. V. has been a net seller over the last 12 months, reducing personal holdings by ₹4.2m.분석 기사 • Feb 15There's Reason For Concern Over Vimta Labs Limited's (NSE:VIMTALABS) Massive 29% Price JumpVimta Labs Limited ( NSE:VIMTALABS ) shares have continued their recent momentum with a 29% gain in the last month...Recent Insider Transactions • Feb 14Key Executive recently sold ₹1.0m worth of stockOn the 6th of February, V. Vungal sold around 975 shares on-market at roughly ₹1,038 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹5.8m. This was V.'s only on-market trade for the last 12 months.분석 기사 • Feb 07Here's Why Vimta Labs (NSE:VIMTALABS) Has Caught The Eye Of InvestorsInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹1,043, the stock trades at a trailing P/E ratio of 42.5x. Average trailing P/E is 49x in the Life Sciences industry in India. Total returns to shareholders of 164% over the past three years.Reported Earnings • Jan 25Third quarter 2025 earnings released: EPS: ₹7.86 (vs ₹4.57 in 3Q 2024)Third quarter 2025 results: EPS: ₹7.86 (up from ₹4.57 in 3Q 2024). Revenue: ₹911.5m (up 12% from 3Q 2024). Net income: ₹175.2m (up 73% from 3Q 2024). Profit margin: 19% (up from 12% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.공시 • Jan 24Vimta Labs Limited Appoints Siva Rama Krishna Kambhampati as Chief Financial Officer, Effective 3 March, 2025Vimta Labs Limited announced that at the board meeting held on January 24, 2025 approved the appointment of Shri. Siva Rama Krishna Kambhampati as Chief Financial Officer of the Company with effect from 3 March, 2025. Shri. Siva Rama Krishna Kambhampati is a seasoned finance professional with experience in Strategic Financial planning, controlling, costing, treasury management and designing internal controls. Experienced in working with cross functional and cross-cultural teams. He has an overall experience of 15 years and has worked with various listed and unlisted companies.공시 • Jan 20Vimta Labs Limited to Report Q3, 2025 Results on Jan 24, 2025Vimta Labs Limited announced that they will report Q3, 2025 results on Jan 24, 2025Valuation Update With 7 Day Price Move • Jan 16Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹825, the stock trades at a trailing P/E ratio of 37.2x. Average trailing P/E is 49x in the Life Sciences industry in India. Total returns to shareholders of 95% over the past three years.New Risk • Jan 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.0% average weekly change). Minor Risk Significant insider selling over the past 3 months (₹21m sold).분석 기사 • Dec 24Vimta Labs Limited's (NSE:VIMTALABS) 30% Share Price Surge Not Quite Adding UpVimta Labs Limited ( NSE:VIMTALABS ) shares have continued their recent momentum with a 30% gain in the last month...공시 • Dec 04Vimta Labs Limited Announces Resignation of Rama Narahai Naidu Dodda as Chief Financial Officer, Effective 10 December 2024Vimta Labs Limited announced that Shri. Rama Narahai Naidu Dodda, Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), has resigned from the services of the Company, with effect from close of business hours on 10 December 2024, as he wants to pursue career opportunities outside Vimta Labs Limited.Recent Insider Transactions • Dec 03Insider recently sold ₹5.8m worth of stockOn the 25th of November, Vasireddi Prasad sold around 7k shares on-market at roughly ₹828 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹26m more than they bought in the last 12 months.Valuation Update With 7 Day Price Move • Nov 26Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹897, the stock trades at a trailing P/E ratio of 40.4x. Average trailing P/E is 49x in the Life Sciences industry in India. Total returns to shareholders of 142% over the past three years.New Risk • Nov 21New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: ₹9.8m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.6% average weekly change). Significant insider selling over the past 3 months (₹9.8m sold).Recent Insider Transactions • Nov 21Insider recently sold ₹3.8m worth of stockOn the 14th of November, Vasireddi Prasad sold around 5k shares on-market at roughly ₹759 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹19m more than they bought in the last 12 months.Reported Earnings • Nov 09Second quarter 2025 earnings released: EPS: ₹7.68 (vs ₹2.85 in 2Q 2024)Second quarter 2025 results: EPS: ₹7.68 (up from ₹2.85 in 2Q 2024). Revenue: ₹854.3m (up 16% from 2Q 2024). Net income: ₹170.2m (up 169% from 2Q 2024). Profit margin: 20% (up from 8.6% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.분석 기사 • Nov 09Subdued Growth No Barrier To Vimta Labs Limited (NSE:VIMTALABS) With Shares Advancing 28%Despite an already strong run, Vimta Labs Limited ( NSE:VIMTALABS ) shares have been powering on, with a gain of 28% in...New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.0% average weekly change).Valuation Update With 7 Day Price Move • Nov 08Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹694, the stock trades at a trailing P/E ratio of 37.4x. Average trailing P/E is 49x in the Life Sciences industry in India. Total returns to shareholders of 98% over the past three years.공시 • Nov 05Vimta Labs Limited to Report Q2, 2025 Results on Nov 08, 2024Vimta Labs Limited announced that they will report Q2, 2025 results on Nov 08, 2024공시 • Oct 11Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million.Thyrocare Technologies Limited (BSE:539871) entered into Business Transfer Agreement to acquire Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million on August 30, 2024. A cash consideration of INR 70 million will be paid by Thyrocare Technologies Limited. For the period ended March 31, 2024 Diagnostics and and pathological services business of Virnta Labs Limited had revenue of INR 296.67 million. Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million on October 11, 2024.New Risk • Sep 19New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: ₹4.9m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Significant insider selling over the past 3 months (₹4.9m sold).분석 기사 • Sep 06There's Reason For Concern Over Vimta Labs Limited's (NSE:VIMTALABS) Massive 31% Price JumpThe Vimta Labs Limited ( NSE:VIMTALABS ) share price has done very well over the last month, posting an excellent gain...Valuation Update With 7 Day Price Move • Aug 28Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹608, the stock trades at a trailing P/E ratio of 32.8x. Average trailing P/E is 46x in the Life Sciences industry in India. Total returns to shareholders of 112% over the past three years.공시 • Jul 18Vimta Labs Limited Approves Dividend for the Year Ended March 31, 2024Vimta Labs Limited announced that at its AGM held on July 18, 2024, shareholders approved the dividend of INR 2 per equity shares for the financial year ended March 31, 2024.공시 • Jul 12Vimta Labs Limited to Report Q1, 2025 Results on Jul 17, 2024Vimta Labs Limited announced that they will report Q1, 2025 results on Jul 17, 2024분석 기사 • Jul 12It Looks Like Shareholders Would Probably Approve Vimta Labs Limited's (NSE:VIMTALABS) CEO Compensation PackageKey Insights Vimta Labs will host its Annual General Meeting on 18th of July Salary of ₹13.4m is part of CEO Harita...Upcoming Dividend • Jul 04Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 11 July 2024. Payment date: 25 July 2024. Payout ratio is a comfortable 11% but the company is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.6%).Recent Insider Transactions • Jun 28Insider recently sold ₹3.5m worth of stockOn the 21st of June, Vasireddi Prasad sold around 7k shares on-market at roughly ₹493 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹35m more than they bought in the last 12 months.Reported Earnings • Jun 26Full year 2024 earnings released: EPS: ₹18.51 (vs ₹21.77 in FY 2023)Full year 2024 results: EPS: ₹18.51 (down from ₹21.77 in FY 2023). Revenue: ₹3.19b (flat on FY 2023). Net income: ₹410.1m (down 15% from FY 2023). Profit margin: 13% (down from 15% in FY 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth.분석 기사 • Jun 12Vimta Labs (NSE:VIMTALABS) Seems To Use Debt Quite SensiblyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...공시 • May 23Vimta Labs Limited, Annual General Meeting, Jul 18, 2024Vimta Labs Limited, Annual General Meeting, Jul 18, 2024, at 10:00 Indian Standard Time.Reported Earnings • May 19Full year 2024 earnings released: EPS: ₹18.51 (vs ₹21.77 in FY 2023)Full year 2024 results: EPS: ₹18.51 (down from ₹21.77 in FY 2023). Revenue: ₹3.22b (up 1.0% from FY 2023). Net income: ₹410.1m (down 15% from FY 2023). Profit margin: 13% (down from 15% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.분석 기사 • Apr 26Market Might Still Lack Some Conviction On Vimta Labs Limited (NSE:VIMTALABS) Even After 26% Share Price BoostVimta Labs Limited ( NSE:VIMTALABS ) shareholders have had their patience rewarded with a 26% share price jump in the...Valuation Update With 7 Day Price Move • Apr 25Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹560, the stock trades at a trailing P/E ratio of 30x. Average trailing P/E is 30x in the Life Sciences industry in India. Total returns to shareholders of 125% over the past three years.Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹434, the stock trades at a trailing P/E ratio of 23.2x. Average trailing P/E is 30x in the Life Sciences industry in India. Total returns to shareholders of 163% over the past three years.Recent Insider Transactions • Feb 28President recently sold ₹982k worth of stockOn the 23rd of February, Suresh Kumar sold around 2k shares on-market at roughly ₹491 per share. This transaction amounted to 40% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Suresh's only on-market trade for the last 12 months.Reported Earnings • Feb 01Third quarter 2024 earnings released: EPS: ₹4.57 (vs ₹4.62 in 3Q 2023)Third quarter 2024 results: EPS: ₹4.57 (down from ₹4.62 in 3Q 2023). Revenue: ₹825.7m (up 6.7% from 3Q 2023). Net income: ₹101.3m (down 1.1% from 3Q 2023). Profit margin: 12% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.공시 • Jan 20Vimta Labs Limited to Report Q3, 2024 Results on Jan 31, 2024Vimta Labs Limited announced that they will report Q3, 2024 results on Jan 31, 2024분석 기사 • Jan 06It's A Story Of Risk Vs Reward With Vimta Labs Limited (NSE:VIMTALABS)When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 31x, you may consider Vimta...Reported Earnings • Nov 01Second quarter 2024 earnings released: EPS: ₹2.85 (vs ₹5.97 in 2Q 2023)Second quarter 2024 results: EPS: ₹2.85 (down from ₹5.97 in 2Q 2023). Revenue: ₹754.5m (down 5.5% from 2Q 2023). Net income: ₹63.3m (down 52% from 2Q 2023). Profit margin: 8.4% (down from 17% in 2Q 2023). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Oct 26Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹497, the stock trades at a trailing P/E ratio of 22.5x. Average trailing P/E is 23x in the Life Sciences industry in India. Total returns to shareholders of 279% over the past three years.Valuation Update With 7 Day Price Move • Aug 18Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹581, the stock trades at a trailing P/E ratio of 26.6x. Average trailing P/E is 24x in the Life Sciences industry in India. Total returns to shareholders of 444% over the past three years.Recent Insider Transactions • Aug 13Insider recently sold ₹4.9m worth of stockOn the 10th of August, Praveena Vasireddi sold around 10k shares on-market at roughly ₹490 per share. This transaction amounted to 8.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹24m more than they bought in the last 12 months.Reported Earnings • Jul 29First quarter 2024 earnings released: EPS: ₹5.51 (vs ₹5.45 in 1Q 2023)First quarter 2024 results: EPS: ₹5.51 (up from ₹5.45 in 1Q 2023). Revenue: ₹840.7m (up 6.2% from 1Q 2023). Net income: ₹122.0m (up 1.3% from 1Q 2023). Profit margin: 14% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹471, the stock trades at a trailing P/E ratio of 21.6x. Average trailing P/E is 31x in the Life Sciences industry in India. Total returns to shareholders of 420% over the past three years.분석 기사 • Jul 14If EPS Growth Is Important To You, Vimta Labs (NSE:VIMTALABS) Presents An OpportunityInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...공시 • Jun 29Vimta Labs Limited Declares Dividend for the Financial Year Ended March 31, 2023Vimta Labs Limited at its 33rd Annual General Meeting held on 28 June 2023, declared a dividend of INR 2 per equity share for the financial year ended March 31, 2023.Upcoming Dividend • Jun 14Upcoming dividend of ₹2.00 per share at 0.5% yieldEligible shareholders must have bought the stock before 21 June 2023. Payment date: 07 July 2023. Payout ratio is a comfortable 9.2% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.7%).분석 기사 • Jun 03Vimta Labs (NSE:VIMTALABS) Has Announced A Dividend Of ₹2.00The board of Vimta Labs Limited ( NSE:VIMTALABS ) has announced that it will pay a dividend on the 7th of July, with...공시 • Jun 02+ 1 more updateVimta Labs Limited to Report Q4, 2024 Results on May 30, 2024Vimta Labs Limited announced that they will report Q4, 2024 results on May 30, 2024분석 기사 • May 06Vimta Labs' (NSE:VIMTALABS) Dividend Will Be ₹2.00Vimta Labs Limited ( NSE:VIMTALABS ) will pay a dividend of ₹2.00 on the 7th of July. The dividend yield is 0.5% based...Reported Earnings • May 05Full year 2023 earnings released: EPS: ₹21.77 (vs ₹18.70 in FY 2022)Full year 2023 results: EPS: ₹21.77 (up from ₹18.70 in FY 2022). Revenue: ₹3.22b (up 15% from FY 2022). Net income: ₹481.7m (up 17% from FY 2022). Profit margin: 15% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth.공시 • May 04+ 1 more updateVimta Labs Limited Recommends Dividend for the Financial Year 2022-2023Vimta Labs Limited recommends Dividend of INR 2 (Rupees two only) per share with face value of INR 2 each for the financial year 2022-2023, subject to approval of shareholders in their ensuing Annual General Meeting.Valuation Update With 7 Day Price Move • Feb 03Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹337, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 29x in the Life Sciences industry in India. Total returns to shareholders of 198% over the past three years.Reported Earnings • Jan 30Third quarter 2023 earnings released: EPS: ₹4.62 (vs ₹5.28 in 3Q 2022)Third quarter 2023 results: EPS: ₹4.62 (down from ₹5.28 in 3Q 2022). Revenue: ₹773.8m (up 15% from 3Q 2022). Net income: ₹102.4m (down 12% from 3Q 2022). Profit margin: 13% (down from 17% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 51% per year, which means it is significantly lagging earnings growth.분석 기사 • Dec 07A Look At The Intrinsic Value Of Vimta Labs Limited (NSE:VIMTALABS)Today we will run through one way of estimating the intrinsic value of Vimta Labs Limited ( NSE:VIMTALABS ) by taking...Recent Insider Transactions • Nov 26President recently sold ₹2.3m worth of stockOn the 21st of November, Suresh Kumar sold around 5k shares on-market at roughly ₹463 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹16m. This was Suresh's only on-market trade for the last 12 months.Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. Additional Non-Executive Independent Director Yadagiri Pendri was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Nov 08Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹481, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 35x in the Life Sciences industry in India. Total returns to shareholders of 397% over the past three years.분석 기사 • Nov 06Here's Why We Think Vimta Labs (NSE:VIMTALABS) Might Deserve Your Attention TodayFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Recent Insider Transactions • Nov 05Insider recently sold ₹16m worth of stockOn the 2nd of November, Rajya Vasireddi sold around 40k shares on-market at roughly ₹408 per share. This transaction amounted to 95% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Board Change • Aug 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. Additional Non-Executive Independent Director Yadagiri Pendri was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jul 26First quarter 2023 earnings released: EPS: ₹5.45 (vs ₹3.65 in 1Q 2022)First quarter 2023 results: EPS: ₹5.45 (up from ₹3.65 in 1Q 2022). Revenue: ₹800.2m (up 30% from 1Q 2022). Net income: ₹120.4m (up 49% from 1Q 2022). Profit margin: 15% (up from 13% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year whereas the company’s share price has increased by 56% per year.Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹372, the stock trades at a trailing P/E ratio of 18.6x. Average trailing P/E is 33x in the Life Sciences industry in India. Total returns to shareholders of 114% over the past three years.예정된 배당 지급오늘May 22 2026배당락일Jun 18 2026배당 지급일Jul 08 202620 days (배당락일 기준)다음 배당금을 받으려면 앞으로 27 days일 이내에 매수하세요지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: VIMTALABS 의 배당금 지급은 지난 10 년 동안 휘발성이었습니다.배당금 증가: VIMTALABS 의 배당금 지급은 지난 10 년 동안 증가했습니다.배당 수익률 vs 시장Vimta Labs 배당 수익률 vs 시장VIMTALABS의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (VIMTALABS)0.4%시장 하위 25% (IN)0.3%시장 상위 25% (IN)1.5%업계 평균 (Life Sciences)0.4%분석가 예측 (VIMTALABS) (최대 3년)n/a주목할만한 배당금: VIMTALABS 의 배당금( 0.44% )은 Indian 시장에서 배당금 지급자의 하위 25%( 0.3% )보다 높습니다.고배당: VIMTALABS 의 배당금( 0.44% )은 Indian 시장에서 배당금 지급자의 상위 25%( 1.48% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 낮은 배당금 지급 비율 (11.5%)로 인해 VIMTALABS의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: 현금 지급 비율 ( 18.9% )이 낮기 때문에 VIMTALABS 의 배당금 지급은 현금 흐름으로 잘 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIN 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 06:46종가2026/05/21 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Vimta Labs Limited는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Rohit Bhat360 ONE Capital Market Private LimitedVijay MadunalaFirstCall Research
공시 • May 07Vimta Labs Limited announces Annual dividend, payable on July 08, 2026Vimta Labs Limited announced Annual dividend of INR 2.0000 per share payable on July 08, 2026, ex-date on June 18, 2026 and record date on June 18, 2026.
공시 • Jun 07Vimta Labs Limited Approves Dividend for the Financial Year Ended March 31, 2025Vimta Labs Limited announced at annual general meeting held on June 6, 2025, the shareholders approved to declare a dividend of INR 2 per equity share for the financial year ended March 31, 2025.
Upcoming Dividend • May 23Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 30 May 2025. Payment date: 16 June 2025. Payout ratio is a comfortable 6.7% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.4%).
공시 • Jul 18Vimta Labs Limited Approves Dividend for the Year Ended March 31, 2024Vimta Labs Limited announced that at its AGM held on July 18, 2024, shareholders approved the dividend of INR 2 per equity shares for the financial year ended March 31, 2024.
Upcoming Dividend • Jul 04Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 11 July 2024. Payment date: 25 July 2024. Payout ratio is a comfortable 11% but the company is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.6%).
공시 • Jun 29Vimta Labs Limited Declares Dividend for the Financial Year Ended March 31, 2023Vimta Labs Limited at its 33rd Annual General Meeting held on 28 June 2023, declared a dividend of INR 2 per equity share for the financial year ended March 31, 2023.
분석 기사 • May 16Do Vimta Labs' (NSE:VIMTALABS) Earnings Warrant Your Attention?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
New Risk • May 15New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
Reported Earnings • May 07Full year 2026 earnings released: EPS: ₹17.40 (vs ₹15.01 in FY 2025)Full year 2026 results: EPS: ₹17.40 (up from ₹15.01 in FY 2025). Revenue: ₹4.16b (up 21% from FY 2025). Net income: ₹775.1m (up 16% from FY 2025). Profit margin: 19% (in line with FY 2025). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.
공시 • May 07Vimta Labs Limited announces Annual dividend, payable on July 08, 2026Vimta Labs Limited announced Annual dividend of INR 2.0000 per share payable on July 08, 2026, ex-date on June 18, 2026 and record date on June 18, 2026.
공시 • May 06Vimta Labs Limited, Annual General Meeting, Jun 25, 2026Vimta Labs Limited, Annual General Meeting, Jun 25, 2026.
New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
분석 기사 • Jan 30Vimta Labs Limited (NSE:VIMTALABS) May Have Run Too Fast Too Soon With Recent 29% Price PlummetTo the annoyance of some shareholders, Vimta Labs Limited ( NSE:VIMTALABS ) shares are down a considerable 29% in the...
Reported Earnings • Jan 29Third quarter 2026 earnings released: EPS: ₹3.96 (vs ₹3.93 in 3Q 2025)Third quarter 2026 results: EPS: ₹3.96 (up from ₹3.93 in 3Q 2025). Revenue: ₹1.00b (up 12% from 3Q 2025). Net income: ₹175.9m (flat on 3Q 2025). Profit margin: 18% (down from 20% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.
분석 기사 • Jan 14Estimating The Fair Value Of Vimta Labs Limited (NSE:VIMTALABS)Key Insights Vimta Labs' estimated fair value is ₹510 based on 2 Stage Free Cash Flow to Equity With ₹550 share price...
Buy Or Sell Opportunity • Jan 07Now 21% overvaluedOver the last 90 days, the stock has fallen 14% to ₹618. The fair value is estimated to be ₹510, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has grown by 16%.
Buy Or Sell Opportunity • Dec 22Now 20% overvaluedOver the last 90 days, the stock has fallen 18% to ₹619. The fair value is estimated to be ₹515, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has grown by 16%.
Buy Or Sell Opportunity • Nov 25Now 20% overvaluedOver the last 90 days, the stock has fallen 2.6% to ₹615. The fair value is estimated to be ₹512, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has grown by 16%.
Reported Earnings • Nov 04Second quarter 2026 earnings released: EPS: ₹4.46 (vs ₹3.84 in 2Q 2025)Second quarter 2026 results: EPS: ₹4.46 (up from ₹3.84 in 2Q 2025). Revenue: ₹1.05b (up 23% from 2Q 2025). Net income: ₹199.2m (up 17% from 2Q 2025). Profit margin: 19% (down from 20% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Sep 02Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹764, the stock trades at a trailing P/E ratio of 47.3x. Average trailing P/E is 41x in the Life Sciences industry in India. Total returns to shareholders of 333% over the past three years.
분석 기사 • Aug 28Some Shareholders Feeling Restless Over Vimta Labs Limited's (NSE:VIMTALABS) P/E RatioVimta Labs Limited's ( NSE:VIMTALABS ) price-to-earnings (or "P/E") ratio of 39.2x might make it look like a sell right...
Valuation Update With 7 Day Price Move • Jul 28Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹659, the stock trades at a trailing P/E ratio of 40.7x. Average trailing P/E is 53x in the Life Sciences industry in India. Total returns to shareholders of 229% over the past three years.
Reported Earnings • Jul 18First quarter 2026 earnings released: EPS: ₹4.25 (vs ₹2.77 in 1Q 2025)First quarter 2026 results: EPS: ₹4.25 (up from ₹2.77 in 1Q 2025). Revenue: ₹993.1m (up 22% from 1Q 2025). Net income: ₹188.9m (up 54% from 1Q 2025). Profit margin: 19% (up from 15% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Jun 12New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
공시 • Jun 07Vimta Labs Limited Approves Dividend for the Financial Year Ended March 31, 2025Vimta Labs Limited announced at annual general meeting held on June 6, 2025, the shareholders approved to declare a dividend of INR 2 per equity share for the financial year ended March 31, 2025.
분석 기사 • May 31Vimta Labs Limited's (NSE:VIMTALABS) CEO Looks Like They Deserve Their Pay PacketKey Insights Vimta Labs' Annual General Meeting to take place on 6th of June Total pay for CEO Harita Vasireddi...
Upcoming Dividend • May 23Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 30 May 2025. Payment date: 16 June 2025. Payout ratio is a comfortable 6.7% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.4%).
공시 • May 16Vimta Labs Limited, Annual General Meeting, Jun 06, 2025Vimta Labs Limited, Annual General Meeting, Jun 06, 2025, at 10:00 Indian Standard Time.
Reported Earnings • May 16Full year 2025 earnings released: EPS: ₹30.28 (vs ₹18.51 in FY 2024)Full year 2025 results: EPS: ₹30.28 (up from ₹18.51 in FY 2024). Revenue: ₹3.48b (up 9.1% from FY 2024). Net income: ₹667.6m (up 63% from FY 2024). Profit margin: 19% (up from 13% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth.
분석 기사 • May 16Here's Why Vimta Labs (NSE:VIMTALABS) Has Caught The Eye Of InvestorsInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
공시 • May 15+ 3 more updatesVimta Labs Limited to Report First Half, 2026 Results on Nov 14, 2025Vimta Labs Limited announced that they will report first half, 2026 results on Nov 14, 2025
공시 • Apr 24Vimta Labs Limited to Report Q4, 2025 Results on Apr 28, 2025Vimta Labs Limited announced that they will report Q4, 2025 results on Apr 28, 2025
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹853, the stock trades at a trailing P/E ratio of 34.7x. Average trailing P/E is 43x in the Life Sciences industry in India. Total returns to shareholders of 128% over the past three years.
Valuation Update With 7 Day Price Move • Mar 10Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹1,003, the stock trades at a trailing P/E ratio of 40.6x. Average trailing P/E is 48x in the Life Sciences industry in India. Total returns to shareholders of 198% over the past three years.
Valuation Update With 7 Day Price Move • Feb 21Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹947, the stock trades at a trailing P/E ratio of 38.6x. Average trailing P/E is 50x in the Life Sciences industry in India. Total returns to shareholders of 197% over the past three years.
Recent Insider Transactions • Feb 19Key Executive recently sold ₹3.1m worth of stockOn the 12th of February, V. Vungal sold around 3k shares on-market at roughly ₹1,084 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹5.8m. V. has been a net seller over the last 12 months, reducing personal holdings by ₹4.2m.
분석 기사 • Feb 15There's Reason For Concern Over Vimta Labs Limited's (NSE:VIMTALABS) Massive 29% Price JumpVimta Labs Limited ( NSE:VIMTALABS ) shares have continued their recent momentum with a 29% gain in the last month...
Recent Insider Transactions • Feb 14Key Executive recently sold ₹1.0m worth of stockOn the 6th of February, V. Vungal sold around 975 shares on-market at roughly ₹1,038 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹5.8m. This was V.'s only on-market trade for the last 12 months.
분석 기사 • Feb 07Here's Why Vimta Labs (NSE:VIMTALABS) Has Caught The Eye Of InvestorsInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹1,043, the stock trades at a trailing P/E ratio of 42.5x. Average trailing P/E is 49x in the Life Sciences industry in India. Total returns to shareholders of 164% over the past three years.
Reported Earnings • Jan 25Third quarter 2025 earnings released: EPS: ₹7.86 (vs ₹4.57 in 3Q 2024)Third quarter 2025 results: EPS: ₹7.86 (up from ₹4.57 in 3Q 2024). Revenue: ₹911.5m (up 12% from 3Q 2024). Net income: ₹175.2m (up 73% from 3Q 2024). Profit margin: 19% (up from 12% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Jan 24Vimta Labs Limited Appoints Siva Rama Krishna Kambhampati as Chief Financial Officer, Effective 3 March, 2025Vimta Labs Limited announced that at the board meeting held on January 24, 2025 approved the appointment of Shri. Siva Rama Krishna Kambhampati as Chief Financial Officer of the Company with effect from 3 March, 2025. Shri. Siva Rama Krishna Kambhampati is a seasoned finance professional with experience in Strategic Financial planning, controlling, costing, treasury management and designing internal controls. Experienced in working with cross functional and cross-cultural teams. He has an overall experience of 15 years and has worked with various listed and unlisted companies.
공시 • Jan 20Vimta Labs Limited to Report Q3, 2025 Results on Jan 24, 2025Vimta Labs Limited announced that they will report Q3, 2025 results on Jan 24, 2025
Valuation Update With 7 Day Price Move • Jan 16Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹825, the stock trades at a trailing P/E ratio of 37.2x. Average trailing P/E is 49x in the Life Sciences industry in India. Total returns to shareholders of 95% over the past three years.
New Risk • Jan 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.0% average weekly change). Minor Risk Significant insider selling over the past 3 months (₹21m sold).
분석 기사 • Dec 24Vimta Labs Limited's (NSE:VIMTALABS) 30% Share Price Surge Not Quite Adding UpVimta Labs Limited ( NSE:VIMTALABS ) shares have continued their recent momentum with a 30% gain in the last month...
공시 • Dec 04Vimta Labs Limited Announces Resignation of Rama Narahai Naidu Dodda as Chief Financial Officer, Effective 10 December 2024Vimta Labs Limited announced that Shri. Rama Narahai Naidu Dodda, Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), has resigned from the services of the Company, with effect from close of business hours on 10 December 2024, as he wants to pursue career opportunities outside Vimta Labs Limited.
Recent Insider Transactions • Dec 03Insider recently sold ₹5.8m worth of stockOn the 25th of November, Vasireddi Prasad sold around 7k shares on-market at roughly ₹828 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹26m more than they bought in the last 12 months.
Valuation Update With 7 Day Price Move • Nov 26Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹897, the stock trades at a trailing P/E ratio of 40.4x. Average trailing P/E is 49x in the Life Sciences industry in India. Total returns to shareholders of 142% over the past three years.
New Risk • Nov 21New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: ₹9.8m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.6% average weekly change). Significant insider selling over the past 3 months (₹9.8m sold).
Recent Insider Transactions • Nov 21Insider recently sold ₹3.8m worth of stockOn the 14th of November, Vasireddi Prasad sold around 5k shares on-market at roughly ₹759 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹19m more than they bought in the last 12 months.
Reported Earnings • Nov 09Second quarter 2025 earnings released: EPS: ₹7.68 (vs ₹2.85 in 2Q 2024)Second quarter 2025 results: EPS: ₹7.68 (up from ₹2.85 in 2Q 2024). Revenue: ₹854.3m (up 16% from 2Q 2024). Net income: ₹170.2m (up 169% from 2Q 2024). Profit margin: 20% (up from 8.6% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.
분석 기사 • Nov 09Subdued Growth No Barrier To Vimta Labs Limited (NSE:VIMTALABS) With Shares Advancing 28%Despite an already strong run, Vimta Labs Limited ( NSE:VIMTALABS ) shares have been powering on, with a gain of 28% in...
New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.0% average weekly change).
Valuation Update With 7 Day Price Move • Nov 08Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹694, the stock trades at a trailing P/E ratio of 37.4x. Average trailing P/E is 49x in the Life Sciences industry in India. Total returns to shareholders of 98% over the past three years.
공시 • Nov 05Vimta Labs Limited to Report Q2, 2025 Results on Nov 08, 2024Vimta Labs Limited announced that they will report Q2, 2025 results on Nov 08, 2024
공시 • Oct 11Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million.Thyrocare Technologies Limited (BSE:539871) entered into Business Transfer Agreement to acquire Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million on August 30, 2024. A cash consideration of INR 70 million will be paid by Thyrocare Technologies Limited. For the period ended March 31, 2024 Diagnostics and and pathological services business of Virnta Labs Limited had revenue of INR 296.67 million. Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million on October 11, 2024.
New Risk • Sep 19New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: ₹4.9m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Significant insider selling over the past 3 months (₹4.9m sold).
분석 기사 • Sep 06There's Reason For Concern Over Vimta Labs Limited's (NSE:VIMTALABS) Massive 31% Price JumpThe Vimta Labs Limited ( NSE:VIMTALABS ) share price has done very well over the last month, posting an excellent gain...
Valuation Update With 7 Day Price Move • Aug 28Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹608, the stock trades at a trailing P/E ratio of 32.8x. Average trailing P/E is 46x in the Life Sciences industry in India. Total returns to shareholders of 112% over the past three years.
공시 • Jul 18Vimta Labs Limited Approves Dividend for the Year Ended March 31, 2024Vimta Labs Limited announced that at its AGM held on July 18, 2024, shareholders approved the dividend of INR 2 per equity shares for the financial year ended March 31, 2024.
공시 • Jul 12Vimta Labs Limited to Report Q1, 2025 Results on Jul 17, 2024Vimta Labs Limited announced that they will report Q1, 2025 results on Jul 17, 2024
분석 기사 • Jul 12It Looks Like Shareholders Would Probably Approve Vimta Labs Limited's (NSE:VIMTALABS) CEO Compensation PackageKey Insights Vimta Labs will host its Annual General Meeting on 18th of July Salary of ₹13.4m is part of CEO Harita...
Upcoming Dividend • Jul 04Upcoming dividend of ₹2.00 per shareEligible shareholders must have bought the stock before 11 July 2024. Payment date: 25 July 2024. Payout ratio is a comfortable 11% but the company is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.6%).
Recent Insider Transactions • Jun 28Insider recently sold ₹3.5m worth of stockOn the 21st of June, Vasireddi Prasad sold around 7k shares on-market at roughly ₹493 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹35m more than they bought in the last 12 months.
Reported Earnings • Jun 26Full year 2024 earnings released: EPS: ₹18.51 (vs ₹21.77 in FY 2023)Full year 2024 results: EPS: ₹18.51 (down from ₹21.77 in FY 2023). Revenue: ₹3.19b (flat on FY 2023). Net income: ₹410.1m (down 15% from FY 2023). Profit margin: 13% (down from 15% in FY 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth.
분석 기사 • Jun 12Vimta Labs (NSE:VIMTALABS) Seems To Use Debt Quite SensiblyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
공시 • May 23Vimta Labs Limited, Annual General Meeting, Jul 18, 2024Vimta Labs Limited, Annual General Meeting, Jul 18, 2024, at 10:00 Indian Standard Time.
Reported Earnings • May 19Full year 2024 earnings released: EPS: ₹18.51 (vs ₹21.77 in FY 2023)Full year 2024 results: EPS: ₹18.51 (down from ₹21.77 in FY 2023). Revenue: ₹3.22b (up 1.0% from FY 2023). Net income: ₹410.1m (down 15% from FY 2023). Profit margin: 13% (down from 15% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.
분석 기사 • Apr 26Market Might Still Lack Some Conviction On Vimta Labs Limited (NSE:VIMTALABS) Even After 26% Share Price BoostVimta Labs Limited ( NSE:VIMTALABS ) shareholders have had their patience rewarded with a 26% share price jump in the...
Valuation Update With 7 Day Price Move • Apr 25Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹560, the stock trades at a trailing P/E ratio of 30x. Average trailing P/E is 30x in the Life Sciences industry in India. Total returns to shareholders of 125% over the past three years.
Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹434, the stock trades at a trailing P/E ratio of 23.2x. Average trailing P/E is 30x in the Life Sciences industry in India. Total returns to shareholders of 163% over the past three years.
Recent Insider Transactions • Feb 28President recently sold ₹982k worth of stockOn the 23rd of February, Suresh Kumar sold around 2k shares on-market at roughly ₹491 per share. This transaction amounted to 40% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Suresh's only on-market trade for the last 12 months.
Reported Earnings • Feb 01Third quarter 2024 earnings released: EPS: ₹4.57 (vs ₹4.62 in 3Q 2023)Third quarter 2024 results: EPS: ₹4.57 (down from ₹4.62 in 3Q 2023). Revenue: ₹825.7m (up 6.7% from 3Q 2023). Net income: ₹101.3m (down 1.1% from 3Q 2023). Profit margin: 12% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Jan 20Vimta Labs Limited to Report Q3, 2024 Results on Jan 31, 2024Vimta Labs Limited announced that they will report Q3, 2024 results on Jan 31, 2024
분석 기사 • Jan 06It's A Story Of Risk Vs Reward With Vimta Labs Limited (NSE:VIMTALABS)When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 31x, you may consider Vimta...
Reported Earnings • Nov 01Second quarter 2024 earnings released: EPS: ₹2.85 (vs ₹5.97 in 2Q 2023)Second quarter 2024 results: EPS: ₹2.85 (down from ₹5.97 in 2Q 2023). Revenue: ₹754.5m (down 5.5% from 2Q 2023). Net income: ₹63.3m (down 52% from 2Q 2023). Profit margin: 8.4% (down from 17% in 2Q 2023). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Oct 26Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹497, the stock trades at a trailing P/E ratio of 22.5x. Average trailing P/E is 23x in the Life Sciences industry in India. Total returns to shareholders of 279% over the past three years.
Valuation Update With 7 Day Price Move • Aug 18Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹581, the stock trades at a trailing P/E ratio of 26.6x. Average trailing P/E is 24x in the Life Sciences industry in India. Total returns to shareholders of 444% over the past three years.
Recent Insider Transactions • Aug 13Insider recently sold ₹4.9m worth of stockOn the 10th of August, Praveena Vasireddi sold around 10k shares on-market at roughly ₹490 per share. This transaction amounted to 8.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹24m more than they bought in the last 12 months.
Reported Earnings • Jul 29First quarter 2024 earnings released: EPS: ₹5.51 (vs ₹5.45 in 1Q 2023)First quarter 2024 results: EPS: ₹5.51 (up from ₹5.45 in 1Q 2023). Revenue: ₹840.7m (up 6.2% from 1Q 2023). Net income: ₹122.0m (up 1.3% from 1Q 2023). Profit margin: 14% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹471, the stock trades at a trailing P/E ratio of 21.6x. Average trailing P/E is 31x in the Life Sciences industry in India. Total returns to shareholders of 420% over the past three years.
분석 기사 • Jul 14If EPS Growth Is Important To You, Vimta Labs (NSE:VIMTALABS) Presents An OpportunityInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
공시 • Jun 29Vimta Labs Limited Declares Dividend for the Financial Year Ended March 31, 2023Vimta Labs Limited at its 33rd Annual General Meeting held on 28 June 2023, declared a dividend of INR 2 per equity share for the financial year ended March 31, 2023.
Upcoming Dividend • Jun 14Upcoming dividend of ₹2.00 per share at 0.5% yieldEligible shareholders must have bought the stock before 21 June 2023. Payment date: 07 July 2023. Payout ratio is a comfortable 9.2% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.7%).
분석 기사 • Jun 03Vimta Labs (NSE:VIMTALABS) Has Announced A Dividend Of ₹2.00The board of Vimta Labs Limited ( NSE:VIMTALABS ) has announced that it will pay a dividend on the 7th of July, with...
공시 • Jun 02+ 1 more updateVimta Labs Limited to Report Q4, 2024 Results on May 30, 2024Vimta Labs Limited announced that they will report Q4, 2024 results on May 30, 2024
분석 기사 • May 06Vimta Labs' (NSE:VIMTALABS) Dividend Will Be ₹2.00Vimta Labs Limited ( NSE:VIMTALABS ) will pay a dividend of ₹2.00 on the 7th of July. The dividend yield is 0.5% based...
Reported Earnings • May 05Full year 2023 earnings released: EPS: ₹21.77 (vs ₹18.70 in FY 2022)Full year 2023 results: EPS: ₹21.77 (up from ₹18.70 in FY 2022). Revenue: ₹3.22b (up 15% from FY 2022). Net income: ₹481.7m (up 17% from FY 2022). Profit margin: 15% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth.
공시 • May 04+ 1 more updateVimta Labs Limited Recommends Dividend for the Financial Year 2022-2023Vimta Labs Limited recommends Dividend of INR 2 (Rupees two only) per share with face value of INR 2 each for the financial year 2022-2023, subject to approval of shareholders in their ensuing Annual General Meeting.
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹337, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 29x in the Life Sciences industry in India. Total returns to shareholders of 198% over the past three years.
Reported Earnings • Jan 30Third quarter 2023 earnings released: EPS: ₹4.62 (vs ₹5.28 in 3Q 2022)Third quarter 2023 results: EPS: ₹4.62 (down from ₹5.28 in 3Q 2022). Revenue: ₹773.8m (up 15% from 3Q 2022). Net income: ₹102.4m (down 12% from 3Q 2022). Profit margin: 13% (down from 17% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 51% per year, which means it is significantly lagging earnings growth.
분석 기사 • Dec 07A Look At The Intrinsic Value Of Vimta Labs Limited (NSE:VIMTALABS)Today we will run through one way of estimating the intrinsic value of Vimta Labs Limited ( NSE:VIMTALABS ) by taking...
Recent Insider Transactions • Nov 26President recently sold ₹2.3m worth of stockOn the 21st of November, Suresh Kumar sold around 5k shares on-market at roughly ₹463 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹16m. This was Suresh's only on-market trade for the last 12 months.
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. Additional Non-Executive Independent Director Yadagiri Pendri was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Nov 08Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹481, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 35x in the Life Sciences industry in India. Total returns to shareholders of 397% over the past three years.
분석 기사 • Nov 06Here's Why We Think Vimta Labs (NSE:VIMTALABS) Might Deserve Your Attention TodayFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Recent Insider Transactions • Nov 05Insider recently sold ₹16m worth of stockOn the 2nd of November, Rajya Vasireddi sold around 40k shares on-market at roughly ₹408 per share. This transaction amounted to 95% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Board Change • Aug 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. Additional Non-Executive Independent Director Yadagiri Pendri was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jul 26First quarter 2023 earnings released: EPS: ₹5.45 (vs ₹3.65 in 1Q 2022)First quarter 2023 results: EPS: ₹5.45 (up from ₹3.65 in 1Q 2022). Revenue: ₹800.2m (up 30% from 1Q 2022). Net income: ₹120.4m (up 49% from 1Q 2022). Profit margin: 15% (up from 13% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year whereas the company’s share price has increased by 56% per year.
Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹372, the stock trades at a trailing P/E ratio of 18.6x. Average trailing P/E is 33x in the Life Sciences industry in India. Total returns to shareholders of 114% over the past three years.